Angiomyolipoma & Oncocytoma

You are staring at a kidney with a lump in it, and the whole game is one question: is this thing trying to hurt the patient, or is it a harmless freeloader? Most of the time you cannot be sure. But these two masses are special. One of them, angiomyolipoma, hands you a gift you almost never get in renal imaging: a confident "benign." The other, oncocytoma, is the con artist who looks exactly like the dangerous guy and gets away with it constantly. The framework that decides which pathway a solid mass takes lives in Approach to the Renal Mass; this page is the two benign characters in that story.

Angiomyolipoma: the fatty one

The name is a recipe card. Angio (blood vessels), myo (smooth muscle), lipoma (fat). It is a benign tumor made of those three ingredients in whatever ratio it feels like that day, and the fat is the part you care about, because macroscopic fat inside a renal mass is the single most useful finding in this whole topic.

Why does fat matter so much? Because fat has a distinctive fingerprint. On CT, every voxel gets a number in Hounsfield units, and fat sits in negative territory. The ACR white paper's rule is simple: a region of interest inside the mass that measures < −10 HU is macroscopic fat, and a fat-containing renal mass goes down the angiomyolipoma flowchart rather than the cancer one. You have caught the AML red-handed.

The catch (there's always a catch)

Two wrinkles keep AML from being a free lunch.

First, fat-poor AML. A minority of these tumors are stingy with the fat: there is not enough of it in any one voxel to pull the number below −10 HU, so the lesion just looks like a solid enhancing mass. And a solid enhancing renal mass with no visible fat is, until proven otherwise, an RCC. Fat-poor AMLs are the reason "no fat" never lets you off the hook; absence of fat proves nothing. (How large that minority is, and what it looks like on MRI, is something I'm not going to put a number on, so I will leave it as "a minority" rather than quote a figure.)

Second, size and bleeding. AMLs are full of abnormal, fragile vessels, and the big ones can bleed spontaneously into the retroperitoneum. That, not malignancy, is why AMLs get treated. The ACR white paper's referral thresholds for prophylactic treatment are an AML ≥4 cm or an aneurysm >0.5 cm within it; the 4 cm cutoff traces back to Oesterling's original surgical series. A symptomatic AML (hematuria, flank pain, spontaneous bleeding) is referred regardless of size.

Multiple bilateral AMLs are a classic association with tuberous sclerosis, so if you see kidneys peppered with fatty lesions, that diagnosis should pop into your head, along with the question of whether any of them has crossed the 4 cm line.

Oncocytoma: the convincing impostor

Now the frustrating one. Oncocytoma is a benign solid renal tumor, and on imaging it wants desperately to be mistaken for the most common kidney cancer, clear cell RCC. It is a well-defined, solid, avidly enhancing mass, which is exactly what a worrying RCC looks like.

Textbooks describe two features that lean toward oncocytoma: a central scar (a stellate area in the middle that does not enhance) and a spoke-wheel pattern of vessels radiating outward like bicycle spokes. They sound great. The problem is that RCC can show a central scar too, and many oncocytomas do not have one. How often the scar is present is not a number I'm going to give you, and I would not trust one anyway, because the point is that it fails in both directions.

Here is the honest bottom line, and it is worth sitting with: imaging cannot reliably distinguish oncocytoma from RCC. Even biopsy is tricky, because oncocytoma and the chromophobe subtype of RCC share overlapping cells under the microscope. The practical consequence is that most of these masses are still biopsied, resected, or ablated, because nobody wants to gamble a kidney cancer on a maybe.

Findings by modality

CT

• AML, classic: a well-defined cortical mass, often exophytic, with one or more regions measuring < −10 HU on the unenhanced series (the fat), interspersed with enhancing soft tissue (the vessels and muscle). Look for a dilated, tortuous vessel or a rounded enhancing focus that could be an aneurysm; measure it, because >0.5 cm is a referral threshold.
• AML, fat-poor: a homogeneous solid enhancing mass, sometimes slightly hyperattenuating to parenchyma on the unenhanced series, with no voxel below −10 HU. Indistinguishable from RCC on CT.
• Oncocytoma: a well-circumscribed, solid, avidly and often homogeneously enhancing mass; a non-enhancing central stellate scar in some; no macroscopic fat.
• Both: if the mass is solid and enhancing with no fat, apply the size context from the ACR white paper (benign in about 40% under 1 cm, about 20% at 1–4 cm, under 10% above 4 cm) and the stability rule if priors exist.

MRI

• AML: macroscopic fat follows fat on every sequence: bright on T1, and it drops out on fat-suppressed images. India-ink (etching) artifact at fat–water interfaces on opposed-phase imaging marks the boundary of a fatty component. MRI is also the ACR-preferred test for a mass <1.5 cm and for proving enhancement in a hypovascular mass.
• Fat-poor AML: I'm not quoting the MRI signal characteristics that some use to suggest it; the safe statement is that MRI cannot reliably separate fat-poor AML from RCC either.
• Oncocytoma: solid enhancing mass; the scar, when present, is a non-enhancing central region. No sequence separates it from RCC reliably.

Ultrasound

• AML: classically a markedly echogenic cortical mass, often as bright as the renal sinus fat, sometimes with posterior acoustic shadowing. Echogenicity alone is not proof: small RCCs can be echogenic too, so an echogenic mass on ultrasound gets a CT or MRI to look for fat at < −10 HU.
• Oncocytoma: a nonspecific solid mass with internal vascularity; a spoke-wheel Doppler pattern is described but is not diagnostic.

The numbers

How good is the test

There is no robust pooled sensitivity or specificity for CT or MRI at diagnosing angiomyolipoma or at separating oncocytoma from renal cell carcinoma, so I will not quote one. What I can give you is the qualitative position of the ACR white paper: macroscopic fat at < −10 HU is diagnostic of AML, and a solid enhancing mass without fat cannot be called benign on imaging, which is why oncocytoma is usually diagnosed by the pathologist.

The mimics

Reporting

For an AML with unambiguous fat, the referrer needs:

• The word "angiomyolipoma" and the basis: "contains macroscopic fat measuring below −10 HU."
• Size in three planes, and whether it is ≥4 cm.
• Any aneurysm, with its diameter, and whether it is >0.5 cm.
• Symptoms if known (hematuria, flank pain, hemorrhage), because a symptomatic AML is referred at any size.
• Multiplicity and bilaterality, with a nod to tuberous sclerosis when the kidneys are peppered.
• The recommendation: no treatment referral for an asymptomatic AML under 4 cm without an aneurysm; urologic or interventional referral for prophylactic treatment when it reaches 4 cm or carries an aneurysm >0.5 cm.

For a solid enhancing mass without fat, whether you suspect oncocytoma or not:

• Size, location, and the T-category size band it would fall into if malignant.
• Enhancement pattern and any central scar, described as a feature, not a diagnosis.
• A plain statement that oncocytoma and fat-poor angiomyolipoma cannot be excluded on imaging, so that the biopsy conversation happens.
• The stability rule if priors exist: no feature change and growth ≤3 mm per year for at least 5 years ends the workup.

So the takeaway is a tale of two tumors. Find unambiguous fat, and AML gives you the rare luxury of confidence, with two numbers (4 cm, 0.5 cm) that decide what happens next. Oncocytoma gives you nothing but a good-looking lie, which is exactly why, when in doubt with a solid enhancing renal mass, the safe assumption is the one that keeps the patient safe: treat it like cancer until proven otherwise.